Tag: pathologicCompResponse

News

11/19/12

Traditional prognostic factors may not predict recurrence after PCR

08/01/11

BC subtype influences prognosis after neoadjuvant chemotherapy

Studies

• Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study Cite
  Parrish KM, Thomas SM, Cartwright SB, van den Bruele AB, Zasloff R, DiLalla GA, et al. Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2024; 10.1245/s10434-024-16026-w
• Nodal Response and Survival After Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer: 20-Year Experience from a Single Institution Cite
  An SJ, Thai CHNC, Ismail S, Agala CB, Hoang V, Feeney T, et al. Nodal Response and Survival After Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer: 20-Year Experience from a Single Institution. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2024; 10.1245/s10434-024-16059-1
• Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer: a multicenter prospective cohort study in the Setouchi Breast Project-14 Cite
  Nakamoto S, Kajiwara Y, Taniguchi K, Hida AI, Miyoshi Y, Kin T, et al. Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer: a multicenter prospective cohort study in the Setouchi Breast Project-14. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07395-7
• Evaluating gut microbiome as a biomarker of pathological complete response in patients with early locally advanced triple negative breast cancer (LA TNBC): A pilot study. Cite
  Sarfraz H, Czerniecki BJ, Stankiewicz K, Jaglal MV, Jain S, Yadav H, et al. Evaluating gut microbiome as a biomarker of pathological complete response in patients with early locally advanced triple negative breast cancer (LA TNBC): A pilot study.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2024; 42:593-593 10.1200/jco.2024.42.16_suppl.593
• Comparison of the Pathological Complete Response Rate and Survival between HER2-low and HER2-zero Breast Cancer in Neoadjuvant Chemotherapy Setting: a Systematic Review and Meta-analysis Cite
  Liu M, Xiang Q, Dai F, Yuan Y, Wu Z, Xiang T. Comparison of the Pathological Complete Response Rate and Survival between HER2-low and HER2-zero Breast Cancer in Neoadjuvant Chemotherapy Setting: a Systematic Review and Meta-analysis. Clinical Breast Cancer. Elsevier BV; 2024; 10.1016/j.clbc.2024.05.001
• Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer Cite
  Chen W, Zhang J, Li F, Chen Z, Li J, Lu D. Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer. World Journal of Surgical Oncology. Springer Science and Business Media LLC; 2024; 22 10.1186/s12957-024-03366-w
• Abstract PO3-03-01: Impact of Environmental Temperature on Clinical Outcomes and Tumor Microenvironment of Early-Stage Breast Cancer Cite
  Roy AM, Rosario S, George A, Hu Q, Czerniecki B, Carpten J, et al. Abstract PO3-03-01: Impact of Environmental Temperature on Clinical Outcomes and Tumor Microenvironment of Early-Stage Breast Cancer. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:PO3-03-01-PO3-03-01 10.1158/1538-7445.sabcs23-po3-03-01
• Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis Cite
  Liu Z, Li J, Zhao F, Ren D, Li Z, Chen Y, et al. Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis. BMC Cancer. Springer Science and Business Media LLC; 2024; 24 10.1186/s12885-024-12222-9
• Associations of pre-diagnosis physical activity with treatment tolerance and treatment efficacy in breast cancer patients with neoadjuvant chemotherapy Cite
  Lin D, Sturgeon KM, Muscat JE, Zhou S, Hobkirk AL, O’Brien KM, et al. Associations of pre-diagnosis physical activity with treatment tolerance and treatment efficacy in breast cancer patients with neoadjuvant chemotherapy. Breast Cancer. Springer Science and Business Media LLC; 2024; 10.1007/s12282-024-01569-3
• Mammographic density changes after neoadjuvant chemotherapy in triple-negative breast cancer: Association with treatment and survival outcome Cite
  Choi Y, Kim S, Cho N, Moon WK. Mammographic density changes after neoadjuvant chemotherapy in triple-negative breast cancer: Association with treatment and survival outcome. Clinical Imaging. Elsevier BV; 2024; 109:110136 10.1016/j.clinimag.2024.110136
• Clinical Outcomes and Intrinsic Subtypes of Breast Cancer Patients with Single Hormone Receptor-positive Receiving Neoadjuvant Chemotherapy Cite
  Wang T, Wang J, Zhao W, Pan Y. Clinical Outcomes and Intrinsic Subtypes of Breast Cancer Patients with Single Hormone Receptor-positive Receiving Neoadjuvant Chemotherapy. Clinical Breast Cancer. Elsevier BV; 2024; 10.1016/j.clbc.2024.02.016
• Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy Cite
  Woriax HE, Thomas SM, Plichta JK, Rosenberger LH, Botty van den Bruele A, Chiba A, et al. Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2024; 10.1200/jco.23.01199
• Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery? Cite
  van de Loo ME, Andour L, van Heesewijk AE, Oosterkamp HM, Liefers G, Straver ME. Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-023-07222-5
• High linoleic acid levels in red blood cells predict a poor response to neoadjuvant chemotherapy in HER2-positive breast cancer patients Cite
  Valenzuela R, Walbaum B, Farias C, Acevedo F, Vargas C, Bennett JT, et al. High linoleic acid levels in red blood cells predict a poor response to neoadjuvant chemotherapy in HER2-positive breast cancer patients. Nutrition. Elsevier BV; 2024;:112357 10.1016/j.nut.2024.112357
• Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer Cite
  Myers SP, Sevilimedu V, Barrio AV, Tadros AB, Mamtani A, Robson ME, et al. Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-14319-0
• Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study Cite
  Sanft T, Harrigan M, McGowan C, Cartmel B, Zupa M, Li F, et al. Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2023; 10.1200/jco.23.00871
• Association of Antibiotic Exposure with Residual Cancer Burden and Pathologic Complete Response in Patients with HER2-negative stage II or III breast cancer Treated with Neoadjuvant Pembrolizumab in the ISPY-2 Trial Cite
  Kulkarni A, Jain A, Jewett P, Desai N, Veer LV', Hirst G, et al. Association of Antibiotic Exposure with Residual Cancer Burden and Pathologic Complete Response in Patients with HER2-negative stage II or III breast cancer Treated with Neoadjuvant Pembrolizumab in the ISPY-2 Trial. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-3179847/v1
• Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis Cite
  Ploumen RAW, Claassens EL, Kooreman LFS, Keymeulen KBMI, van Kats MACE, Gommers S, et al. Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07012-z
• Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis Cite
  Chen L, Wu F, Chen X, Chen Y, Deng L, Cai Q, et al. Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis. npj Breast Cancer. Springer Science and Business Media LLC; 2023; 9 10.1038/s41523-023-00552-z
• Epstein-Barr virus in breast carcinoma and in triple negative cases impact on clinical outcomes Cite
  Mekrazi S, Kallel I, Jamai D, Yengui M, Khabir A, Gdoura R. Epstein-Barr virus in breast carcinoma and in triple negative cases impact on clinical outcomes. Pathology - Research and Practice. Elsevier BV; 2023; 245:154484 10.1016/j.prp.2023.154484
• Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer Cite
  Zhao F, Miyashita M, Hattori M, Yoshimatsu T, Howard F, Kaneva K, et al. Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. JAMA Network Open. American Medical Association (AMA); 2023; 6:e233329 10.1001/jamanetworkopen.2023.3329
• Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer Cite
  Kuhar CG, Borštnar S, Gazić B, Matos E. Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer. The Breast. Elsevier BV; 2023; 10.1016/j.breast.2023.01.011
• Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy Cite
  Jiang C, Xiu Y, Yu X, Qiao K, Zhang S, Huang Y. Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy. BMC Cancer. Springer Science and Business Media LLC; 2022; 22 10.1186/s12885-022-10291-2
• Aspirin Use is Associated with Improvement in Distant Metastases Outcome in Patients with Residual Disease after Neoadjuvant Chemotherapy Cite
  Johns C, Cauble M, Liu Y, Rahimi A, Alluri P, Nwachukwu C, et al. Aspirin Use is Associated with Improvement in Distant Metastases Outcome in Patients with Residual Disease after Neoadjuvant Chemotherapy. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2022; 114:e5 10.1016/j.ijrobp.2022.07.683
• Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review Cite
  Garutti M, Griguolo G, Botticelli A, Buzzatti G, De Angelis C, Gerratana L, et al. Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review. Cancers. MDPI AG; 2022; 14:1898 10.3390/cancers14081898
• Abstract P3-18-03: Long-term outcomes for breast conservation plus radiotherapy versus mastectomy in early breast cancer after neoadjuvant systemic therapy: Results from the Swedish national breast cancer register (NKBC) Cite
  Wang K, Duinmeijer A, Matikas A, Altena R, Johansson H, Fredholm H, et al. Abstract P3-18-03: Long-term outcomes for breast conservation plus radiotherapy versus mastectomy in early breast cancer after neoadjuvant systemic therapy: Results from the Swedish national breast cancer register (NKBC). Cancer Research. American Association for Cancer Research (AACR); 2022; 82:P3-18-03-P3-18-03 10.1158/1538-7445.sabcs21-p3-18-03
• Mammographic density to predict response to neoadjuvant systemic breast cancer therapy Cite
  Di Cosimo S, Depretto C, Miceli R, Baili P, Ljevar S, Sant M, et al. Mammographic density to predict response to neoadjuvant systemic breast cancer therapy. Journal of Cancer Research and Clinical Oncology. Springer Science and Business Media LLC; 2022; 10.1007/s00432-021-03881-3
• Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients Cite
  Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. The Lancet Oncology. Elsevier BV; 2021; 10.1016/s1470-2045(21)00589-1
• Factors associated with relapse-free survival after neoadjuvant chemotherapy for breast cancer at a safety net medical center Cite
  Sargent RE, Vazquez E, Kang I, Lu J, Manchandia T, Sheth P, et al. Factors associated with relapse-free survival after neoadjuvant chemotherapy for breast cancer at a safety net medical center. The American Journal of Surgery. Elsevier BV; 2021; 10.1016/j.amjsurg.2021.11.017
• The effects of vitamin D (Vit D) replacement on pathological complete response (PCR) in breast cancer (BC) patients receiving neoadjuvant systemic chemotherapy (NAC). Cite
  Ozmen V, Ordu C, Ilgun AS, Unal C, Soybir G, Erdogan Z, et al. The effects of vitamin D (Vit D) replacement on pathological complete response (PCR) in breast cancer (BC) patients receiving neoadjuvant systemic chemotherapy (NAC).. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2021; 39:e12604-e12604 10.1200/jco.2021.39.15_suppl.e12604
• Predictors of Nodal Pathological Complete Response in Asian Women with Stage II–III Node-Positive Breast Cancer Cite
  Montagna G, Tong Y, Ritter M, Levi J, Weber WP, Chen X, et al. Predictors of Nodal Pathological Complete Response in Asian Women with Stage II–III Node-Positive Breast Cancer. Oncology. S. Karger AG; 2021;:1-6 10.1159/000513454
• Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials Cite
  Villegas SL, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, et al. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials. European Journal of Cancer. Elsevier BV; 2021; 148:159-170 10.1016/j.ejca.2021.02.020
• Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer Cite
  Katayama A, Miligy IM, Shiino S, Toss MS, Eldib K, Kurozumi S, et al. Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. Modern Pathology. Springer Science and Business Media LLC; 2021; 10.1038/s41379-021-00738-5
• Breast radiologic complete response is associated with favorable survival outcomes after neoadjuvant chemotherapy in breast cancer Cite
  Woo J, Ryu JM, Jung SM, Choi HJ, Lee SK, Yu J, et al. Breast radiologic complete response is associated with favorable survival outcomes after neoadjuvant chemotherapy in breast cancer. European Journal of Surgical Oncology. Elsevier BV; 2020; 10.1016/j.ejso.2020.08.023
• The Tumor–Fat Interface Volume of Breast Cancer on Pretreatment MRI Is Associated with a Pathologic Response to Neoadjuvant Chemotherapy Cite
  Cho H, Park M, Park H, Ko ES, Hwang NY, Im Y, et al. The Tumor–Fat Interface Volume of Breast Cancer on Pretreatment MRI Is Associated with a Pathologic Response to Neoadjuvant Chemotherapy. Biology. MDPI AG; 2020; 9:391 10.3390/biology9110391
• Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial Cite
  Di Cosimo S, Porcu L, Agbor-tarh D, Cinieri S, Franzoi MA, De Santis MC, et al. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. Breast Cancer Research. Springer Science and Business Media LLC; 2020; 22 10.1186/s13058-020-01356-w
• Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes? Cite
  Lai V, Hajjaj O, Le D, Shokoohi A, Chia S, Simmons C. Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 184:755-762 10.1007/s10549-020-05894-x
• Risk Factors for Ipsilateral Breast Tumor Recurrence in Triple-Negative or HER2-Positive Breast Cancer Patients Who Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy Cite
  Ishitobi M, Matsuda N, Tazo M, Nakayama S, Tokui R, Ogawa T, et al. Risk Factors for Ipsilateral Breast Tumor Recurrence in Triple-Negative or HER2-Positive Breast Cancer Patients Who Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 10.1245/s10434-020-09176-0
• Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment? Cite
  Alan O, Akin Telli T, Aktas B, Koca S, Ökten IN, Hasanov R, et al. Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?. World Journal of Surgical Oncology. Springer Science and Business Media LLC; 2020; 18 10.1186/s12957-020-02019-y
• Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial Cite
  de Groot S, Lugtenberg RT, Cohen D, Welters MJP, Ehsan I, Vreeswijk MPG, et al. Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nature Communications. Springer Science and Business Media LLC; 2020; 11 10.1038/s41467-020-16138-3
• Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor‐positive breast cancer patients Cite
  Boland MR, Ryan ÉJ, Nugent T, Gilroy D, Kelly ME, Kennedy J, et al. Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor‐positive breast cancer patients. Journal of Surgical Oncology. Wiley; 2020; 10.1002/jso.26096
• Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients Cite
  Schneider J, Lee HJ, Nam SJ, Lee SJ, Jung JH, Jung SH, et al. Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients. Journal of Breast Cancer. Korean Breast Cancer Society; 2020; 23:259 10.4048/jbc.2020.23.e34
• Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy Cite
  Hamy A, Darrigues L, Laas E, De Croze D, Topciu L, Lam G, et al. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy. PLOS ONE. Public Library of Science (PLoS); 2020; 15:e0234191 10.1371/journal.pone.0234191
• Risk factors of ipsilateral breast tumor recurrence in triple-negative or HER2-positive breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy. Cite
  Tazo M, Kojima Y, Yoshida A, Nakayama S, Tokui R, Ogawa T, et al. Risk factors of ipsilateral breast tumor recurrence in triple-negative or HER2-positive breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:e12599-e12599 10.1200/jco.2020.38.15_suppl.e12599
• Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation Cite
  Keilty D, Nezafat Namini S, Swain M, Maganti M, Cil TD, McCready DR, et al. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2020; 108:676-685 10.1016/j.ijrobp.2020.04.044
• Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials Cite
  Werutsky G, Untch M, Hanusch C, Fasching PA, Blohmer J, Seiler S, et al. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. European Journal of Cancer. Elsevier BV; 2020; 130:92-101 10.1016/j.ejca.2020.02.015
• Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy Cite
  Samiei S, van Nijnatten TJA, de Munck L, Keymeulen KBMI, Simons JM, Kooreman LFS, et al. Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy. Annals of Surgery. Ovid Technologies (Wolters Kluwer Health); 2020; 271:574-580 10.1097/sla.0000000000003126
• Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis Cite
  Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, et al. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clinical Cancer Research. American Association for Cancer Research (AACR); 2020; 26:2838-2848 10.1158/1078-0432.ccr-19-3492
• Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis Cite
  Yau C, van der Noordaa M, Wei J, Osdoit M, Reyal F, Hamy A, et al. Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis. General Session Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7445.sabcs19-gs5-01
• Outcomes for Patients with Residual Stage II/III Breast Cancer Following Neoadjuvant Chemotherapy (AFT-01) Cite
  Stankowski-Drengler TJ, Schumacher JR, Hanlon B, Livingston-Rosanoff D, Van de Walle K, Greenberg CC, et al. Outcomes for Patients with Residual Stage II/III Breast Cancer Following Neoadjuvant Chemotherapy (AFT-01). Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 27:637-644 10.1245/s10434-019-07846-2
• Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy Cite
  Asaoka M, Narui K, Suganuma N, Chishima T, Yamada A, Sugae S, et al. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy. European Journal of Surgical Oncology. Elsevier BV; 2019; 45:2289-2294 10.1016/j.ejso.2019.08.001
• Diabetes Mellitus and Metformin Are Not Associated With Breast Cancer Pathologic Complete Response Cite
  Hassinger TE, Berger AC, Christopher A, Knisely AT, Mehaffey JH, Brenin DR, et al. Diabetes Mellitus and Metformin Are Not Associated With Breast Cancer Pathologic Complete Response. Journal of Surgical Research. Elsevier BV; 2020; 247:52-58 10.1016/j.jss.2019.10.043
• Survival Outcomes for Patients With Clinical Complete Response After Neoadjuvant Chemotherapy: Is Omitting Surgery an Option? Cite
  Özkurt E, Sakai T, Wong SM, Tukenmez M, Golshan M. Survival Outcomes for Patients With Clinical Complete Response After Neoadjuvant Chemotherapy: Is Omitting Surgery an Option?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2019; 26:3260-3268 10.1245/s10434-019-07534-1
• Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials Cite
  Werutsky G, Untch M, Hanusch C, Fasching P, Blohmer J, Seiler S, et al. Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials. Annals of Oncology. Elsevier BV; 2019; 30:v62-v63 10.1093/annonc/mdz240.014
• Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database Cite
  Bagegni NA, Tao Y, Ademuyiwa FO. Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database. PLOS ONE. Public Library of Science (PLoS); 2019; 14:e0222358 10.1371/journal.pone.0222358
• A Nomogram to Predict the Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Laboratory Indicators Cite
  Zhang F, Huang M, Zhou H, Chen K, Jin J, Wu Y, et al. A Nomogram to Predict the Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Laboratory Indicators. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2019; 26:3912-3919 10.1245/s10434-019-07655-7
• Impact of serum vitamin D on the response and the prognosis in breast cancer patients treated with neoadjuvant chemotherapy. Cite
  Tokunaga E, Masuda T, Ijichi H, Koga C, Tajiri W, Tanaka J, et al. Impact of serum vitamin D on the response and the prognosis in breast cancer patients treated with neoadjuvant chemotherapy.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:e12088-e12088 10.1200/jco.2019.37.15_suppl.e12088
• Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice Cite
  Saw S, Lim J, Lim SH, Wong M, Lim C, Yap YS. Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 177:197-206 10.1007/s10549-019-05290-0
• Association between pre-diagnosis BMI, physical activity, pathologic complete response, and chemotherapy completion in women treated with neoadjuvant chemotherapy for breast cancer Cite
  Usiskin I, Li F, Irwin ML, Cartmel B, Sanft T. Association between pre-diagnosis BMI, physical activity, pathologic complete response, and chemotherapy completion in women treated with neoadjuvant chemotherapy for breast cancer. Breast Cancer. Springer Science and Business Media LLC; 2019; 26:719-728 10.1007/s12282-019-00974-3
• Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer Cite
  van Uden DJP, van Maaren MC, Bult P, Strobbe LJA, van der Hoeven JJM, Blanken-Peeters CFJM, et al. Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 176:217-226 10.1007/s10549-019-05219-7
• Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy Cite
  Wang X, He Y, Fan Z, Wang T, Xie Y, Li J, et al. Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy. Breast Care. S. Karger AG; 2019; 14:388-393 10.1159/000495186
• Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy Cite
  Goto W, Kashiwagi S, Takada K, Asano Y, Takahashi K, Fujita H, et al. Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy. Journal of Translational Medicine. Springer Science and Business Media LLC; 2018; 16 10.1186/s12967-018-1679-0
• Predictors of Pathological Complete Response in Women with Clinical Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma Cite
  Resende U, Cabello C, Oliveira Botelho Ramalho S, Zeferino L. Predictors of Pathological Complete Response in Women with Clinical Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma. Oncology. S. Karger AG; 2018; 95:229-238 10.1159/000489785
• Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response Cite
  Kozak MM, Jacobson CE, von Eyben R, Pollom EL, Telli M, Horst KC. Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response. Journal of the National Comprehensive Cancer Network. Harborside Press, LLC; 2018; 16:845-850 10.6004/jnccn.2018.7022
• High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy Cite
  Fujimoto Y, Higuchi T, Nishimukai A, Miyagawa Y, Kira A, Ozawa H, et al. High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy. Journal of Surgical Oncology. Wiley; 2018; 118:228-237 10.1002/jso.25125
• Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes Cite
  Kogawa T, Fujii T, Fouad TM, Liu DD, Harano K, Masuda H, et al. Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 171:501-511 10.1007/s10549-018-4853-4
• Ki67 to predict RCB0/I after neoadjuvant chemotherapy and endocrine therapy in HER2- breast cancer patients from ABCSG 34. Cite
  Singer CF, Rudas M, Fesl C, Steger GG, Pfeiler G, Egle D, et al. Ki67 to predict RCB0/I after neoadjuvant chemotherapy and endocrine therapy in HER2- breast cancer patients from ABCSG 34.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018; 36:589-589 10.1200/jco.2018.36.15_suppl.589
• Low Estrogen Receptor (ER)–Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy Cite
  Landmann A, Farrugia DJ, Zhu L, Diego EJ, Johnson RR, Soran A, et al. Low Estrogen Receptor (ER)–Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy. American Journal of Clinical Pathology. Oxford University Press (OUP); 2018; 150:34-42 10.1093/ajcp/aqy028
• Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy Cite
  Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh BS. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 170:559-567 10.1007/s10549-018-4801-3
• Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer Cite
  Chiba A, Raman R, Thomas A, Lamy P, Viala M, Pouderoux S, et al. Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2018; 18:144-149 10.1016/j.clbc.2017.12.001
• Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer Cite
  Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, et al. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. Journal of the National Comprehensive Cancer Network. Harborside Press, LLC; 2017; 15:1216-1223 10.6004/jnccn.2017.0158
• Young Women Who Achieve Pathologic Complete Response in the Axillary Lymph Nodes Do Not Have Improved Survival Compared to Those Who Remain Lymph Node Positive after Neoadjuvant Chemotherapy Cite
  Kozak M, Jacobson C, Horst K. Young Women Who Achieve Pathologic Complete Response in the Axillary Lymph Nodes Do Not Have Improved Survival Compared to Those Who Remain Lymph Node Positive after Neoadjuvant Chemotherapy. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2017; 99:E26 10.1016/j.ijrobp.2017.06.653
• Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer Cite
  Chen VE, Gillespie EF, Zakeri K, Murphy JD, Yashar CM, Lu S, et al. Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer. Advances in Radiation Oncology. Elsevier BV; 2017; 2:105-109 10.1016/j.adro.2017.01.012
• Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial Cite
  Kimbung S, Markholm I, Bjöhle J, Lekberg T, von Wachenfeldt A, Azavedo E, et al. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial. International Journal of Cancer. Wiley; 2017; 142:618-628 10.1002/ijc.31070
• Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers Cite
  Monneur A, Goncalves A, Gilabert M, Finetti P, Tarpin C, Zemmour C, et al. Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers. Oncotarget. Impact Journals, LLC; 2017; 8:66019-66032 10.18632/oncotarget.19732
• Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials Cite
  van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, Marmé F, et al. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 167:59-71 10.1007/s10549-017-4480-5
• Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy Cite
  Petruolo OA, Pilewskie M, Patil S, Barrio AV, Stempel M, Wen HY, et al. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:2556-2562 10.1245/s10434-017-5898-z
• Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer Cite
  Hage AN, Capriccioso C, Brennan J, Heiden B, Zheutlin A, Sabel MS. Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer. Journal of Surgical Oncology. Wiley; 2017; 116:665-670 10.1002/jso.24721
• The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer Cite
  Nakhlis F, Regan MM, Warren LE, Bellon JR, Hirshfield-Bartek J, Duggan MM, et al. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:2563-2569 10.1245/s10434-017-5903-6
• Abstract P6-09-24: Vitamin D level impacts odds of pathologic complete response following neoadjuvant therapy in operable breast cancer Cite
  Thomas A, Thezenas S, Mott S, Raman R, Viala M, Pouderoux S, et al. Abstract P6-09-24: Vitamin D level impacts odds of pathologic complete response following neoadjuvant therapy in operable breast cancer. Poster Session Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-p6-09-24
• Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) Cite
  Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, et al. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:1061-1069 10.1200/jco.2016.69.4406
• Outcome after neoadjuvant chemotherapy in Asian breast cancer patients Cite
  Lim LY, Miao H, Lim JSJ, Lee SC, Bhoo-Pathy N, Yip CH, et al. Outcome after neoadjuvant chemotherapy in Asian breast cancer patients. Cancer Medicine. Wiley; 2016; 6:173-185 10.1002/cam4.985
• Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis Cite
  Jiang T, Shi W, Wali VB, Pongor LS, Li C, Lau R, et al. Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. PLOS Medicine. Public Library of Science (PLoS); 2016; 13:e1002193 10.1371/journal.pmed.1002193
• Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy Cite
  Kasimir-Bauer S, Bittner A, König L, Reiter K, Keller T, Kimmig R, et al. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy. Breast Cancer Research. Springer Science and Business Media LLC; 2016; 18 10.1186/s13058-016-0679-3
• Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Cite
  Jung YY, Hyun CL, Jin M, Park IA, Chung YR, Shim B, et al. Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Journal of Breast Cancer. Korean Breast Cancer Society; 2016; 19:261 10.4048/jbc.2016.19.3.261
• Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database Cite
  Liu J, Chen K, Jiang W, Mao K, Li S, Kim MJ, et al. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database. Journal of Cancer Research and Clinical Oncology. Springer Science and Business Media LLC; 2016; 143:161-168 10.1007/s00432-016-2281-6
• Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426) Cite
  Warner ET, Ballman KV, Strand C, Boughey JC, Buzdar AU, Carey LA, et al. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 159:109-118 10.1007/s10549-016-3918-5
• Effect of Body Mass Index– and Actual Weight–Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer Cite
  Raman R, Mott SL, Schroeder MC, Phadke S, El Masri J, Thomas A. Effect of Body Mass Index– and Actual Weight–Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2016; 16:480-486 10.1016/j.clbc.2016.06.008
• Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer Cite
  De Iuliis F, Salerno G, Corvino R, D'Aniello D, Cefalì K, Taglieri L, et al. Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2017; 17:34-40 10.1016/j.clbc.2016.06.010
• Effect of Body Mass Index– and Actual Weight–Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer Cite
  Raman R, Mott SL, Schroeder MC, Phadke S, El Masri J, Thomas A. Effect of Body Mass Index– and Actual Weight–Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2016; 16:480-486 10.1016/j.clbc.2016.06.008
• Neoadjuvant chemotherapy in breast-conserving surgery – Consequences on margin status and excision volumes Cite
  Volders J, Haloua M, Krekel N, Negenborn V, Barbé E, Sietses C, et al. Neoadjuvant chemotherapy in breast-conserving surgery – Consequences on margin status and excision volumes. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2016; 42:986-993 10.1016/j.ejso.2016.02.252
• Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy Cite
  Baron P, Beitsch P, Boselli D, Symanowski J, Pellicane JV, Beatty J, et al. Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2015; 23:1522-1529 10.1245/s10434-015-5030-1
• Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer – a Single Centre Study. (PPLB – 01) Cite
  Agrawal S, Banswal L, Saha A, Arun I, Datta SS, Chatterjee S, et al. Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer – a Single Centre Study. (PPLB – 01). Indian Journal of Surgical Oncology. Springer Science and Business Media LLC; 2016; 7:397-406 10.1007/s13193-016-0523-3
• Parsing Pathologic Complete Response in Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer Cite
  Morrow M. Parsing Pathologic Complete Response in Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer. JAMA Oncology. American Medical Association (AMA); 2016; 2:516 10.1001/jamaoncol.2015.4919
• Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands Cite
  Vugts G, Maaskant-Braat A, de Roos W, Voogd A, Nieuwenhuijzen G. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2016; 42:956-964 10.1016/j.ejso.2016.03.023
• Abstract P6-12-06: Preoperative chemotherapy regimens and breast cancer subtype in an underinsured Hispanic population Cite
  Mehta D, Winton L, Walters J, Hsu C, Nodora J, Martinez M, et al. Abstract P6-12-06: Preoperative chemotherapy regimens and breast cancer subtype in an underinsured Hispanic population. Poster Session Abstracts. American Association for Cancer Research; 2016; 10.1158/1538-7445.sabcs15-p6-12-06
• Abstract P5-08-48: Vitamin D deficiency in various breast cancer subtypes and its impact on response to neoadjuvant chemotherapy in operable breast cancer Cite
  Raman R, Link B, Mott S, Schroeder M, Thomas A. Abstract P5-08-48: Vitamin D deficiency in various breast cancer subtypes and its impact on response to neoadjuvant chemotherapy in operable breast cancer. Poster Session Abstracts. American Association for Cancer Research; 2016; 10.1158/1538-7445.sabcs15-p5-08-48
• High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer Cite
  Alba E, Lluch A, Ribelles N, Anton‐Torres A, Sanchez‐Rovira P, Albanell J, et al. High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. The Oncologist. Wiley; 2016; 21:150-155 10.1634/theoncologist.2015-0312
• Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer Cite
  Korn E, Sachs M, McShane L. Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer. Annals of Oncology. Elsevier BV; 2016; 27:10-15 10.1093/annonc/mdv507
• Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry Cite
  Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry. Annals of Oncology. Elsevier BV; 2016; 27:480-487 10.1093/annonc/mdv611
• Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base Cite
  Killelea BK, Yang VQ, Wang S, Hayse B, Mougalian S, Horowitz NR, et al. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:4267-4276 10.1200/jco.2015.63.7801
• Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy Cite
  Baulies S, Belin L, Mallon P, Senechal C, Pierga J, Cottu P, et al. Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy. British Journal of Cancer. Springer Science and Business Media LLC; 2015; 113:30-36 10.1038/bjc.2015.174
• Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer Cite
  Kim T, Han W, Kim MK, Lee JW, Kim J, Ahn SK, et al. Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. Journal of Breast Cancer. Korean Breast Cancer Society; 2015; 18:16 10.4048/jbc.2015.18.1.16
• Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer Cite
  Wang C, Zhang J, Wang Y, Ouyang T, Li J, Wang T, et al. Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer. Annals of Oncology. Elsevier BV; 2015; 26:523-528 10.1093/annonc/mdu559
• Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer Cite
  Horimoto Y, Arakawa A, Tanabe M, Sonoue H, Igari F, Senuma K, et al. Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer. BMC Cancer. Springer Science and Business Media LLC; 2014; 14 10.1186/1471-2407-14-550
• Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Cite
  Kim KI, Lee KH, Kim TR, Chun YS, Lee TH, Park HK. Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. Journal of Breast Cancer. Korean Breast Cancer Society; 2014; 17:40 10.4048/jbc.2014.17.1.40
• Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial Cite
  Bonnefoi H, Litière S, Piccart M, MacGrogan G, Fumoleau P, Brain E, et al. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Annals of Oncology. Elsevier BV; 2014; 25:1128-1136 10.1093/annonc/mdu118
• Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Cite
  Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet. Elsevier BV; 2014; 384:164-172 10.1016/s0140-6736(13)62422-8
• Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer Cite
  Kim M, Allen P, Gonzalez-Angulo A, Woodward W, Meric-Bernstam F, Buzdar A, et al. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Annals of Oncology. Elsevier BV; 2013; 24:1999-2004 10.1093/annonc/mdt131
• Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27 Cite
  Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE, et al. Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:3960-3966 10.1200/jco.2011.40.8369
• Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy Cite
  Ju NR, Jeffe DB, Keune J, Aft R. Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 137:195-201 10.1007/s10549-012-2312-1
• Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab Cite
  Ohzawa H, Sakatani T, Niki T, Yasuda Y, Hozumi Y. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab. Breast Cancer. Springer Science and Business Media LLC; 2012; 21:563-570 10.1007/s12282-012-0424-4
• Neoadjuvant chemotherapy in breast cancer—insights from the German experience Cite
  von Minckwitz G. Neoadjuvant chemotherapy in breast cancer—insights from the German experience. Breast Cancer. Springer Science and Business Media LLC; 2012; 19:282-288 10.1007/s12282-012-0393-7
• Pathological response and survival after neoadjuvant therapy for breast cancer: A 30-year study Cite
  Guiu S, Arnould L, Bonnetain F, Dalban C, Favier L, Desmoulins I, et al. Pathological response and survival after neoadjuvant therapy for breast cancer: A 30-year study. The Breast. Elsevier BV; 2013; 22:301-308 10.1016/j.breast.2012.07.012
• Obesity or Overweight Is Associated with Worse Pathological Response to Neoadjuvant Chemotherapy among Chinese Women with Breast Cancer Cite
  Chen S, Chen C, Zhou Y, Zhou R, Yu K, Shao Z. Obesity or Overweight Is Associated with Worse Pathological Response to Neoadjuvant Chemotherapy among Chinese Women with Breast Cancer. PLoS ONE. Public Library of Science (PLoS); 2012; 7:e41380 10.1371/journal.pone.0041380
• Response pattern in 844 patients with infiltrating lobular carcinoma (ILC) of the breast after neoadjuvant chemotherapy. Cite
  Pirvulescu C, Loibl S, Von Minckwitz G, Mau C, Blohmer JU, Costa SD, et al. Response pattern in 844 patients with infiltrating lobular carcinoma (ILC) of the breast after neoadjuvant chemotherapy.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:541-541 10.1200/jco.2012.30.15_suppl.541
• Estrogen receptor positive breast cancer identified by 95-gene classifier as at high risk for relapse shows better response to neoadjuvant chemotherapy Cite
  Tsunashima R, Naoi Y, Kishi K, Baba Y, Shimomura A, Maruyama N, et al. Estrogen receptor positive breast cancer identified by 95-gene classifier as at high risk for relapse shows better response to neoadjuvant chemotherapy. Cancer Letters. Elsevier BV; 2012; 324:42-47 10.1016/j.canlet.2012.04.017
• Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Cite
  Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet. Elsevier BV; 2012; 379:633-640 10.1016/s0140-6736(11)61847-3
• Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment Cite
  Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. Springer Science and Business Media LLC; 2011; 11 10.1186/1471-2407-11-486
• Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients Cite
  Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. European Journal of Cancer. Elsevier BV; 2011; 47:2084-2090 10.1016/j.ejca.2011.06.014
• Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials Cite
  von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 125:145-156 10.1007/s10549-010-1228-x
• Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer Cite
  Sánchez-Muñoz A, García-Tapiador AM, Martínez-Ortega E, Dueñas-García R, Jaén-Morago A, Ortega-Granados AL, et al. Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clinical and Translational Oncology. Springer Science and Business Media LLC; 2008; 10:646-653 10.1007/s12094-008-0265-y